RHUBARB AND ANGIOTENSIN CONVERTING ENZYME INHIBITOR STUDY (RACE) II

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 中国的患者表示，大黄提取物单独使用时相当于ACEI提供的保护。此外，当大黄与血管紧张素转换酶抑制剂联合使用时，大黄的肾脏保护作用似乎是相加的。 大黄提取物是一种中草药制剂，在中国等亚洲国家被广泛用于治疗便秘和慢性肾脏病。其预防慢性肾脏病进展的作用机制尚不清楚，但可能与抑制转化生长因子β和肿瘤坏死因子α有关。 这项拟议的研究将是一项前瞻性、随机、双盲、安慰剂对照研究设计，以评估大黄和血管紧张素转换酶抑制剂在预防成年糖尿病患者慢性肾脏病进展方面的疗效。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients in China has suggested that rhubarb extract when used alone is equivalent to the protection afforded by ACEI. Furthermore when used in combination with ACEI, the renoprotective effect of rhubarb appears to be additive. Rhubarb extract is a chinese herbal preparation that is used extensively in china and other asian countries to treat constipation and CKD. Its mechanism of action in preventing progression of CKD is uncertain but perhaps related to TGF beta and TNF alph inhibition. The proposed study will be a prospective randomized double blinded placebo controlled study design to evaluate the efficacy of Rhubarb in addition to ACEI in proventing progression of CKD in adult patients with diabetes.